Jeffrey D Bornstein
Overview
Explore the profile of Jeffrey D Bornstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
1332
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perrin S, Ladha S, Maragakis N, Rivner M, Katz J, Genge A, et al.
PLoS Med
. 2024 Oct;
21(10):e1004469.
PMID: 39480764
Background: The interaction of CD40L and its receptor CD40 on activated T cells and B cells respectively control pro-inflammatory activation in the pathophysiology of autoimmunity and transplant rejection. Previous studies...
2.
Peyrin-Biroulet L, Loftus Jr E, Colombel J, Danese S, Rogers R, Bornstein J, et al.
Gastroenterology
. 2021 Jun;
161(4):1156-1167.e3.
PMID: 34144047
Background And Aims: VARSITY (An Efficacy and Safety Study of Vedolizumab Intravenous [IV] Compared to Adalimumab Subcutaneous [SC] in Participants With Ulcerative Colitis) showed superior clinical remission and endoscopic improvement...
3.
Sands B, Peyrin-Biroulet L, Loftus Jr E, Danese S, Colombel J, Toruner M, et al.
N Engl J Med
. 2019 Sep;
381(13):1215-1226.
PMID: 31553834
Background: Biologic therapies are widely used in patients with ulcerative colitis. Head-to-head trials of these therapies in patients with inflammatory bowel disease are lacking. Methods: In a phase 3b, double-blind,...
4.
Danese S, Sandborn W, Colombel J, Vermeire S, Glover S, Rimola J, et al.
Gastroenterology
. 2019 Jul;
157(4):1007-1018.e7.
PMID: 31279871
Background & Aims: Vedolizumab is a gut-selective monoclonal antibody for the treatment of moderately to severely active Crohn's disease (CD). We performed a prospective study of endoscopic, radiologic, and histologic...
5.
Kim W, Berg T, Asselah T, Flisiak R, Fung S, Gordon S, et al.
J Hepatol
. 2015 Dec;
64(4):773-80.
PMID: 26626497
Background & Aims: While the gold standard in the assessment of liver fibrosis remains liver biopsy, non-invasive methods have been increasingly used for chronic hepatitis B (CHB). This study aimed...
6.
Buti M, Fung S, Gane E, Afdhal N, Flisiak R, Gurel S, et al.
Hepatol Int
. 2015 Mar;
9(2):243-50.
PMID: 25788199
Background: Phase 3 clinical studies have shown that long-term treatment with tenofovir disoproxil fumarate (TDF) can suppress hepatitis B viral load and promote significant fibrosis regression and cirrhosis reversal in...
7.
Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson I, et al.
Lancet
. 2012 Dec;
381(9865):468-75.
PMID: 23234725
Background: Whether long-term suppression of replication of hepatitis B virus (HBV) has any beneficial effect on regression of advanced liver fibrosis associated with chronic HBV infection remains unclear. We aimed...
8.
Tse F, Barkun J, Romagnuolo J, Friedman G, Bornstein J, Barkun A
HPB (Oxford)
. 2008 Mar;
8(6):409-25.
PMID: 18333096
Evaluation of suspected biliary tract obstruction is a common clinical problem. Clinical data such as history, physical examination, and laboratory tests can accurately identify up to 90% of patients whose...
9.
Heneghan M, Allan M, Bornstein J, Muir A, Tendler D
J Hepatol
. 2006 Aug;
45(4):584-91.
PMID: 16876902
Background/aims: Azathioprine is a key drug in the management of autoimmune hepatitis (AIH), with effects mediated via conversion to 6-thioguanine (6-TG) and 6-methylmercaptopurine (6-MMP), the latter controlled by thiopurine methyltransferase...
10.
Bornstein J, Rockey D
Gastroenterology
. 2004 Nov;
124(4):1157-8.
PMID: 15534980
No abstract available.